{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.7"}]}],"title":"10^-4=< - Max"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7"}]}],"title":"10^-5=< - <10^-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7"}]}],"title":"10^-6=< - <10^-5"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0"}]}],"title":"Negative"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"description":"Rate of MRD will be calculated by the percentage of participants who are MRD-negative.","groups":[{"description":"Participants took ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone were not defined by the protocol but according to the package insert of each drug.","id":"OG000","title":"Ixazomib + Lenalidomide + Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set, defined as all participants who were enrolled into the study and who receive at least one dose of ixazomib.","reportingStatus":"POSTED","timeFrame":"Up to 36 months as a maximum","title":"Rate of Minimal Residual Disease (MRD) Negativity in Bone Marrow in Participants Who Achieved CR","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}